Details for Patent: RE49948
✉ Email this page to a colleague
Which drugs does patent RE49948 protect, and when does it expire?
Patent RE49948 protects WELIREG and is included in one NDA.
This patent has fifty-three patent family members in twenty-eight countries.
Drugs Protected by US Patent RE49948
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | RE49948 | ⤷ Subscribe | Y | Y | TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY | ⤷ Subscribe | ||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | RE49948 | ⤷ Subscribe | Y | Y | TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE49948
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 097600 | ⤷ Subscribe | |||
| Australia | 2014318025 | ⤷ Subscribe | |||
| Canada | 2919397 | ⤷ Subscribe | |||
| China | 105530923 | ⤷ Subscribe | |||
| China | 110372550 | ⤷ Subscribe | |||
| Cuba | 20160030 | ⤷ Subscribe | |||
| Cuba | 24385 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
